Brilinta Review Highlights Evidence Gap On Aspirin Dosing
The right aspirin dose is a looming unknown in dual antiplatelet therapy. However, unless the National Institutes of Health or another entity steps in to run a large, expensive study, it appears likely the question will remain unanswered
You may also be interested in...
AstraZeneca could face a significant commercial challenge for its antiplatelet agent Brilinta (ticagrelor) if, as expected, FDA approves the drug with a recommendation for concomitant use of low-dose aspirin in acute coronary syndrome patients
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011